The effect of tumor necrosis factor-blockade on new bone formation in ankylosing spondylitis

Haroon, Nigil

doi:10.1097/bor.0000000000000077

Cited by 5 publications

(3 citation statements)

References 44 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, the biomechanical stability concept provides a good explanation why it takes sustained control of inflammation to prevent structural disease progression [78][79][80] and also theoretically explains that existing structural damage is a risk factor for further progression as an ankylosed segment will affect the stability and biomechanical stress of other segments positioned above or beneath within the spine.…”

Section: A -Structural Damage In Spondyloarthritismentioning

confidence: 99%

Advances in understanding the pathophysiology of spondyloarthritis

Lories

2018

Best Practice & Research Clinical Rheumatology

View full text Add to dashboard Cite

Progressive understanding of the underlying pathophysiology of axial spondyloarthritis has successfully translated into innovative therapeutic strategies and successful management of patients in the clinic. This review summarizes the key roles of pro-inflammatory cytokines tumor necrosis factor and interleukin-17 in the onset and progression of disease and how these cytokines are instrumental in shaping the concept that enthesitis is a key feature of axial spondyloarthritis. Advances in immunological technologies have lead to the important insight that different cell populations, part of both the innate and adaptive immune system, play a key role in axial spondyloarthritis. Besides inflammation, structural damage to the axial skeleton, in particular progressive ankylosis of the sacroiliac joints and the spine, is key to the outcome of patients. Novel data integrate the role of pro-inflammatory cytokines and enthesitis in this context.

show abstract

Section: A -Structural Damage In Spondyloarthritismentioning

confidence: 99%

Advances in understanding the pathophysiology of spondyloarthritis

Lories

2018

Best Practice & Research Clinical Rheumatology

View full text Add to dashboard Cite

show abstract

“…Hinsichtlich konnten, legen die Ergebnisse neuerer Beobachtungsstudien nahe, dass die Therapie länger als vier Jahre fortgeführt werden muss, um einen solchen Effekt nachzuweisen, und dass dem frühzeitigen Beginn (innerhalb der ersten fünf bis zehn Jahre der Erkrankung) einer anti-TNF-Therapie hierbei eine Schlüsselrolle zukommen könnte (25,26).…”

Section: Tnf-α-inhibitorenunclassified

Aktueller Stand der Therapie der axialen Spondyloarthritis mit biologischen DMARDs

Proft¹,

Poddubnyy²

2017

Arthritis und Rheuma

View full text Add to dashboard Cite

ZusammenfassungInnerhalb der vergangenen Jahre konnten eindeutige Ziele für die Therapie der axSpA definiert werden. Einerseits sind die Verrin gerung der Krankheitsaktivität sowie andererseits die Verhinderung struktureller Schäden als Therapieziele in den Fokus gerückt. NSAR bilden, immer in Kombination mit nichtmedikamentösen Maßnahmen, das Gerüst der grundlegenden Therapiestrategie. Sollten sich diese als nicht ausreichend wirksam zeigen, kommt im Verlauf der Einsatz sogenannter Biologika (bDMARDs) in Frage. Derzeit sind für die Übergruppe der axSpA fünf TNF-Blocker sowie ein Antikörper gegen Interleukin (IL)-17A zugelassen, wobei einer der TNF-Blocker (Infliximab) sowie der IL-17A-Blocker Secukinumab derzeit nur für die röntgenologische Form (ankylosierende Spondylitis – AS) der axSpA die Zulas-sung besitzen. Die Erkrankungsgruppe der SpA stellt aktuell ein „Hot Topic” in der Untersuchung neuer Therapien in der Rheumatologie dar und es werden in näherer Zukunft neue zugelassene Therapiemechanismen erwartet. Der Stellenwert sowie der optimale Zeitpunkt des Einsatzes neuer „mode of actions” im Therapiealgorithmus der axSpA werden sich in der Zukunft herauskristallisieren müssen.

show abstract

“…Two anti-TNF-α antibodies, infliximab and adalimumab, are used for active AS patients with inadequate responses to NSAIDs, and are clinically effective in 60-70 % of these individuals 18) . However, the effects of anti-TNF-α antibodies on radiographic progression in AS is still controversial 19) . Anti-TNF-α antibodies are also used for refractory psoriasis and PsA.…”

Section: Spondyloarthritismentioning

confidence: 99%

Current Status of and Future Perspectives on Biologics in Rheumatic Diseases

Tamura

Tada

2015

Juntendo Medical Journal

View full text Add to dashboard Cite

In recent years, treatment of rheumatoid arthritis (RA) with biological agents, also called biological disease-modifying antirheumatic drugs (bDMARDs), has become standard. bDMARDs are generally used for patients with an inadequate response to methotrexate and/or other conventional DMARDs. Thus far, tumor necrosis factor (TNF) inhibitors, an interleukin 6 inhibitor and a T cell-selective regulatory bDMARD have been approved for RA in Japan. The strategy of RA management has also changed. Clinical remission is recommended as a primary goal of treatment because this may prevent subsequent articular destruction and impairment of joint functions. TNF inhibitors are also prescribed to patients with other inflammatory rheumatic diseases, such as ankylosing spondylitis, psoriatic arthritis and Behcetʼs disease, whose conditions have not adequately responded to conventional therapy. Furthermore, B cell depletion therapy with an anti-CD20 monoclonal antibody is an important option in the treatment of refractory anti-neutrophil cytoplasmic antibody-associated vasculitis, especially in granulomatosis with polyangiitis. In addition, biological agents have also been used for off-label indications. However, these agents are costly and may cause serious infections. This article reviews the current use of biological agents in adult rheumatic diseases.

show abstract

The effect of tumor necrosis factor-blockade on new bone formation in ankylosing spondylitis

Cited by 5 publications

References 44 publications

Advances in understanding the pathophysiology of spondyloarthritis

Advances in understanding the pathophysiology of spondyloarthritis

Aktueller Stand der Therapie der axialen Spondyloarthritis mit biologischen DMARDs

Current Status of and Future Perspectives on Biologics in Rheumatic Diseases

Contact Info

Product

Resources

About